QURE (uniQure NV) Operating Margin %: -1,242.81% (As of Mar. 2026)


QURE uniQure NV QURE
52 GF Score
Price $49.23
GF Value $5.95
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is uniQure NV Operating Margin %?

uniQure NV QURE +0.78% 52 Operating Margin % is -1,242.81% as of Mar. 2026. GuruFocus rates QURE with a GF Score™ of 52/100 and a GF Value™ of $5.95 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 945 Biotechnology companies, uniQure NV ranks worse than 79.05% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. uniQure NV's Operating Income for the three months ended in Mar. 2026 was $-44.27 Mil. uniQure NV's Revenue for the three months ended in Mar. 2026 was $3.56 Mil. Therefore, uniQure NV's Operating Margin % for the quarter that ended in Mar. 2026 was -1,242.81%.

The historical rank and industry rank for uniQure NV's Operating Margin % or its related term are showing as below:

QURE' s Operating Margin % Range Over the Past 10 Years
Min: -1783.03   Med: -596.33   Max: 59.45
Current: -1039.83


QURE's Operating Margin % is ranked worse than
79.05% of 945 companies
in the Biotechnology industry
Industry Median: -86.89 vs QURE: -1039.83

uniQure NV's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

uniQure NV's Operating Income for the three months ended in Mar. 2026 was $-44.27 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-188.14 Mil.


uniQure NV  (NAS:QURE) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


uniQure NV Operating Margin % Related Terms


uniQure NV Operating Margin % Historical Data

* Premium members only.

The historical data trend for uniQure NV's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

uniQure NV Operating Margin % Chart

uniQure NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.45 -135.46 -1,783.03 -671.78 -1,166.77

uniQure NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,384.94 -814.99 -1,337.18 -924.82 -1,242.81

QURE vs NVAX, HRMY, IOVA: Operating Margin % Comparison

For the Biotechnology subindustry, uniQure NV's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


uniQure NV Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Operating Margin % distribution charts can be found below:

* The bar in red indicates where uniQure NV's Operating Margin % falls into.


QURE
52GF Score
uniQure NV QURE
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

uniQure NV Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

uniQure NV's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-187.827 / 16.098
=-1,166.77 %

uniQure NV's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-44.269 / 3.562
=-1,242.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -1,242.81% mean?
uniQure NV (QURE) has a Operating Margin % of -1,242.81% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on uniQure NV and its competitors. According to the industry distribution chart, uniQure NV ranks #747 out of 945 companies in the Biotechnology industry, placing it in the top 79%.
Is uniQure NV's Operating Margin % too high?
uniQure NV's current Operating Margin % is -1,242.81%. Based on the distribution chart, uniQure NV ranks #747 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, uniQure NV has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Operating Margin % compare to NVAX and HRMY?
According to the Biotechnology industry distribution chart, uniQure NV ranks #747 out of 945 companies for Operating Margin %. This places uniQure NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on uniQure NV and its competitors. uniQure NV's current Operating Margin % is -1,242.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (QURE) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.95, compared to a current price of $49.23 — trading 727.4% above its estimated fair value. The current Operating Margin % is -1,242.81%. uniQure NV's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For uniQure NV (QURE), the current Operating Margin % is -1,242.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is uniQure NV (QURE) Overvalued in 2026?

Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued. The current stock price of $49.23 is trading 727.4% above its estimated GF Value™ of $5.95. GuruFocus considers uniQure NV to be Significantly Overvalued.

Key valuation signals for QURE:

  • Operating Margin %: -1,242.81%
  • GF Value™: $5.95 vs. price of $49.23 (727.4% above fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the QURE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


uniQure NV Business Description

Address Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
52GF Score

Get the complete analysis for QURE

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$49.23
Price
$5.95
GF Value